Las enfermedades autoinmune-reumáticas en la epidemia por SAR-COV-2; COVID-19. Estrategias en su manejo y actualización desde la visión de la sociedad cubana de reumatología y su grupo nacional

Gil Alberto Reyes Llerena, Zoila Marlene Guibert Toledano, Alfredo Antonio Hernández Martínez, Zoe Alina Otero González, Eduardo Bicet Dorzón, Roberto Torres Carballeira, José Pedro Martínez Larrarte

Texto completo:

PDF

Resumen

La irrupción de la infección por el nuevo coronavirus SARCOV-2, COVID 19,  en diciembre en Wuhan Provincia de China, ha devenido en una pandemia y emergencia sanitaria dada la deficiencia de terapia antiviral para el síndrome respiratorio agudo que genera con peligro para la vida. El debut de la epidemia fue en China, luego el epicentro se desarrolló en Europa, el norte de Italia que sufrió un duro golpe.  Se calculan a nivel mundial más de 10 millones de personas contagiadas con el virus que ha impactado sobre los sistemas de salud hasta prácticamente su colapso por lo que  se produjeron millares de muertes. Hoy día se ha desplazado el epicentro de la pandemia hacia las Américas.

Palabras clave

enfermedades reumáticas; lupus eritematoso sistémico; artritis reumatoide; virus SARCOV-2; COVID-19

Referencias

Anca D Askanase, Leila Khalili, Jill P Bu Askanase AD, Khalili L, Buyon JP. Thoughts on COVID-19 and autoimmune diseases. Lupus Science & Medicine 2020;7: e000396. doi:10.1136/ lupus-2020-000396

Ennio Giulio Favalli, Francesca Ingegnoli, Roberto Caporali. COVID-19 infection and rheumatoid arthritis: Faraway, so close! Autoimmun Rev. 2020 May; 19(5): 102523.

Boletín informativo sobre la COVID 19. Ministerio de Salud Pública de Cuba. Junio 2019

Jara, Luis J.; Medina, Gabriela; Saavedra, Miguel A Autoimmune manifestations of infections Current Opinion in Rheumatology Número: Volume 30(4), July 2018, p 373-37.

Waldmann H. Mechanisms of immunological tolerance. Clin Biochem 2016; 49:324-328.

Hussin A. Rothan and Siddappa N. Byrareddy. Autoimmun. 2020 May; 109: 102433. 8The epidemiology and pathogenesis of coronavirus disease (COVID-19) outbreak

Little P, Read RC, Amlot R, Chadborn T, Rice C, Bostock J, et al. Reducing risks from coronavirus transmission in the home – the role of viral load. BMJ. 2020;369:m1728. doi:10.1136/bmj. m1728

Yehuda Shoenfeld. Corona (COVID-19) time musings: Our involvement in COVID-19 pathogenesis, diagnosis, treatment and vaccine planning: Autoimmun Rev. 2020 Apr 5 : 102538. doi: 10.1016/j.autrev.2020.102538

Baden Lindsey R., Rubin Eric J. Conid-19 – The search for effective therapy. Editorial. N Engl J Med. 2020 Published on March 18, 2020, POI 10.1056/NEJM.

Krause I., Wu R., Sherer Y., Patanik M., Peter J., Shoenfeld Y. In vitro antiviral and antibacterial activity of commercial intravenous immunoglobulin preparations - a potential role for adjuvant intravenous immunoglobulin therapy in infectious diseases. Transfus Med. 2002;12:133–139. [PubMed] [Google Scholar]

Amador-Patarroyo M, Rodriguez-Rodriguez M, Montoya-Ortiz G. How does age at onset influence the outcome of autoimmune diseases? Autoimmune Dis 2012; 2012:251730.

Goodnow CC, Sprent J, Fazekas de St Groth B, Vinuesa CG. Cellular and genetic mechanisms of self tolerance and autoimmunity. Nature 2005; 435:590-597

Waldmann H. Mechanisms of immunological tolerance. Clin Biochem 2016; 49:324-328

Monsalve DM, Pacheco Y, Acosta-Ampudia Y, et al. Zika virus and autoimmunity. One-step forward. Autoimmun Rev 2017; 16:1237-1245.

Jardim DL, Tsukumo DM, Angerami RN, et al. Autoimmune features caused by dengue fever: a case report. Braz J Infect Dis 2012; 16:92-95.

Young LS, Rickinson AB. Epstein-Barr virus: 40 years on. Nat Rev Cancer 2004; 4:757-768.

Krishnan E, Hubert HB. Ethnicity and mortality from systemic lupus erythematosus in the US. Ann Rheum Dis 2006; 65:1500-1505.

Quintero OL, Rojas-Villarraga A, Mantilla RD, Anaya JM. Autoimmune diseases in the intensive care unit. An update. Autoimmun Rev 2013; 12:380-395.

Reyes Llerena GA. Guibert Toledano M. Hernández Martínez A. Millán JC. Patrón epidemiológico clínico de las espondiloartropatías seronegativas en una cohorte VIH-SIDA. Rev Colomb Reumatolog. 1997;4(4):164-8.

Reyes Llerena GA, Guibert Toledano M, Millán JC. Manifestaciones reumáticas en la epidemia VIH/SIDA en la era previa a la terapia antirretroviral sumamente activa en Cuba. Una puesta al día. Rev Peruana Reumatolog. 2016;22(3):25-33.

Gil Alberto Reyes Llerena1* Marlene Guibert Toledano2 Alexer Torres Figueroa3 Ané Navarro Camero3 Roberto Torres Carballeira2 Gil Reyes Guibert1 Mirta Miranda Ley1 Enfermedades reumáticas y complicaciones metabólicas en pacientes con VIH-SIDA con tratamiento antirretroviral de alta eficiencia. Rev Cubana de Reumatol. 2019; DOI: http://dx.doi.org/10.5281/zenodo.1467765

Gil Alberto Reyes Llerena, Zoila Marlene Guibert Toledano, Alexer Torres Figueroa, Ané Navarro Camero, Madelyn Garcés Martínez, Ramiro Sanchoyerto López, Jorge Pérez Ávila. Lupus eritematosos sistémico en la epidemia VIH/SIDA. Reporte inicial de casos en Cuba Revista cubana de reumatología.

Liao HY, Tao CM, Su J. Concomitant systemic lupus erythematosus and HIV infection: a rare case report and literature review. Medicine 2017; 96:e9337.

Ho So1, Chi Chiu Mok, COVID-19 and Rheumatic Diseases: Practical. Journal Clinical rheumatology Vol.2. No 1. 2020 . 1–4 DOI: 10.1142/S2661341720300025

World Health Organization. Coronavirus disease 2019 (COVID-19) situation report -97.2020. https://www.who.int/ emergencies/diseases/novel-coronavirus-2019/situation-reports

Joo Y.B., Lim Y.-H., Kim K.-J., Park K.-S., Park Y.-J. Respiratory viral infections and the risk of rheumatoid arthritis. Arthritis Res Ther. 2019;21:199. doi: 10.1186/s13075-019-1977-9.

Listing J., Gerhold K., Zink A. The risk of infections associated with rheumatoid arthritis, with its comorbidity and treatment. Rheumatology (Oxford) 2012;52:53–61. doi: 10.1093/rheumatology/kes305

Arleevskaya M.I., Shafigullina A.Z., Filina Y.V., Lemerle J., Renaudineau Y. Associations between viral infection history symptoms, granulocyte reactive oxygen species activity, and active rheumatoid arthritis disease in untreated women at onset: results from a longitudinal cohort study of Tatarstan women. Front Immunol. 2017;8:1725. doi: 10.3389/fimmu.2017.01725

Thurah A, Stengaard-Pedersen K, Axelsen M, Fredberg U, Schougaard LMV, Hjollund NHI, et al. Tele-health followup strategy for tight control of disease activity in rheumatoid arthritis: results of a randomized controlled trial. Arthritis Care Res. 2018;70:353-60.

Doran M.F., Crowson C.S., Pond G.R., O’Fallon W.M., Gabriel S.E. Frequency of infection in patients with rheumatoid arthritis compared with controls: a population-based study. Arthritis Rheum. 2002;46:2287–2293. doi: 10.1002/art.10524. [PubMed] [CrossRef] [Google Scholar

Australian Government Department of Health. Advice for people at risk of coronavirus (COVID-19). 2020. https:// www.health. gov.au/news/health-alerts/novel-coronavirus-2019-ncov- Journal of Clinical Rheumatology and Immunology

McDougall JA, Elizabeth DF, Glover J, Fraenkel L. Telerheumatology: a systematic review. Arthritis Care Res. 2017;69:1546-57.

Chen D, Wu D, Chen H, Yan W, Yang D, Chen G, et al. Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study. BMJ. 2020;368:m1295. doi:10.1136/ bmj.m1091 [Epub ahead of print]

Swiss Federal Office of Public Health. New coronavirus: documents for health professionals. https://www.bag.admin.ch/ bag/de/home/krankheiten/ausbrueche-epidemien-pandemien/ aktuelle-ausbrueche-epidemien/novel-cov/information-fuerdie-aerzteschaft/dokumente-fuer-gesundheitsfachpersonen. html. Accessed March 20,

Little P, Read RC, Amlot R, Chadborn T, Rice C, Bostock J, et al. Reducing risks from coronavirus transmission in the home – the role of viral load. BMJ. 2020;369:m1728. doi:10.1136/bmj. m1728 [Epub ahead of print]

Kuo CF, Chou IJ, Rees F. Temporal relationships between systemic lupus erythematosus and comorbidities. Rheumatology. 2019;58:840-8.

Dougados M, Soubrier M, Antunez A, Balint P, Balsa A, Buch MH, et al. Prevalence of comorbidities in rheumatoid arthritis and evaluation of their monitoring: results of an international, cross-sectional study (COMORA). Ann Rheum Dis. 2013;73: 62-8.

Pedro C. Rodriguez, Roberto Torres-Moya, Gil Reyes Llerena , Claudino Molinerob, Dinorah Pradab, Ana M. Lopez, Isabel M. Hernandez, Maria V. Hernandez, Jose P. Martinez, Xochel Hernandez, Angel Casaco, Mayra Ramos, Yisel Avilad, Yinet Barresed, Enrique Monteroe, Patricia Hernandez. Itolizumab A clinical exploratory study with itolizumab, an anti-CD6 monoclonal antibody, in patients with rheumatoid arthritis a Clinical Research Division, Center of Molecular Immunology, Havana, Cuba

Montero E, Reyes Gil A, , Guiber Toledano M,Torre s O, Rodriguez N, Estrada J. etal. Immunodiagnosis and therapeutic immunosuppression inr heumatoid arthritis with iort1 (anti-CD6) monoclonal antibody. Arthritis Researchand Therapy. 2002;4(Suppl. 1, Article 38):114.

Qiu CC, Caricchio R, Gallucci S. Triggers of autoimmunity: the role of bacterial infections in the extracellular exposure of lupus nuclear autoantigens. Front Immunol 2019;10:2608.

Conigliaro P, Triggianese P, Ballanti E, Perricone C, Perricone R, Chimenti MS. Complement, infection, and autoimmunity. Curr Opin Rheumatol. 2019;31:532-41.

Sawalha AH, Manzi S. Coronavirus Disease-2019: implication for the care and management of patients with systemic lupus erythematosus. Eur J Rheumatol. 2020. doi:10.5152/ eurjrheum.2020.20055 [Epub ahead of print]

EULAR guidance for patients COVID-19 Outnreak. Update 17 March 2020.EULAR Task Force.

Cai K, He J, Wong PKK, Manolios N. The impact of COVID-19 on rheumatology clinical practice and university teaching in Sydney, Australia. Eur J Rheumatol. 2020. doi:10.5152/ eurjrheum.2020.20060 [Epub Ahead of Print]

McDougall JA, Elizabeth DF, Glover J, Fraenkel L. Telerheumatology: a systematic review. Arthritis Care Res. 2017;69:1546-57.

Sara Monti, Silvia Balduzzi, Paolo Delvino, Elisa Bellis, Verdiana Serena Quadrelli,

Carlomaurizio. Clinical course of COVID-19 in a series of patients with chronic arthritis treated with immunosuppressive targeted therapies Ann Rheum Dis 2020;0:1–2. doi:10.1136/annrheumdis-2020-217424

Rheumatic disease and COVID-19: initial data from the COVID-19. Global Rheumatology Alliance provider registries Published Online April 16, 2020 https://doi.org/10.1016/ S2665-9913(20)30095-3

Favalli EG, Ingegnoli F, Cimaz R, et al. What is the true incidence of COVID-19 in patients with rheumatic diseases? BM J. Ann Rheum Dis Epub ahead of print:. doi:10.1136/annrheumdis-2020-217615 1Ann Rheum Dis Month 2020 Vol 0 No 0

Noreña I, Fernández- Ruiz M, Aguado JM. Viral infections in the biologic therapy era. Expert Rev Anti Infect Ther 2018;16:781–91.

D’Antiga L. Coronaviruses and immunosuppressed patients. The facts during the third epidemic. Liver Transpl 2020. doi:10.1002/lt.25756

Shi Y, Wang Y, Shao C, et al. COVID-19 infection: the perspectives on immune responses. Cell Death Differ 2020;382.

ACR. COVID-19. Clinical Guidance for Adult Patients with Rheumatic Diseases. Developed by the ACR COVID-19 Clinical Guidance Task Force This summary was approved by the ACR Board of Directors on April 11, 2020. A full paper was published on April 29, 2020, then copyedited/slightly revised for the Early View version of the journal publication, posted June 5, 2020

Manuel F. Ugarte-Gil, Daniel Wojdyla, Guillermo J. Pons-Estel, Rosana Quintana, José A. Gómez-Puerta, Luis J. Catoggio, Alejandro Alvarellos, Verónica Saurit, Eduardo Borba, Emilia Sato, Lilian Costallat, Nilzio A. Da Silva, Antonio Iglesias-Gamarra, Oscar Neira, Gil Reyes-Llerena, Mario H. Cardiel, Mary Carmen Amigo, Eduardo Acevedo-Vásquez, María H. Esteva-Spinetti, Graciela S. Alarcón and Bernardo A. Pons-Estel. 180433 Predictors of Remission and Low Disease Activity State in Systemic Lupus Erythematosus: Data from a Multiethnic, Multinational Latin American Cohort. The Journal of Rheumatology October 2019, 46 (10) 1299-1308; DOI: https://doi.org/10.3899/jrheum. B M J, Lupus Science and Medicine 2007e00396.doi: 101136/lu0020-000396

Bernardo A Pons-Estel, Eloisa Bonfa, Enrique R Soriano, Mario H Cardiel, Ariel Izcovich, Federico Popoff, Juan M Criniti, Gloria Vásquez, Loreto Massardo, Marlene Guibert-Toledano, Gil Llerena Reyes, Maria Isabel Acosta Colman, Alicia M Aquino, et al and Graciela S Alarcón. First Latin American clinical practice guidelines for the treatment of systemic lupus erythematosus: Latin American Group for the Study of Lupus (GLADEL)–Pan-American League of Associations of Rheumatology (PANLAR) Ann Rheum Dis 2018;0:1–9. doi:10.1136/annrheumdis-2018-213512

Enlaces refback

  • No hay ningún enlace refback.


Copyright (c) 2020 Gil Alberto Reyes Llerena, Marlene Guibert Toledano, Alfredo Antonio Hernández Martínez, Zoe Alina Otero González, Eduardo Bicet Dorzón, Roberto Torres Carballeira, José Pedro Martínez Larrarte

Licencia de Creative Commons
Este obra está bajo una licencia de Creative Commons Reconocimiento-NoComercial 4.0 Internacional.